Dr. Robert Mohney
Head of Clinical Biomarker Services
Robert studied chemistry at undergraduate level and began work as a research lab technician in pathology, where his research helped to characterize the biochemical lesions that underlie defective glycosylphosphatidylinositol (GPI) synthesis in the rare disease paroxysmal nocturnal hemoglobinemia (PNH). This work resulted in his first published manuscript and first scientific presentation, in Cambridge UK in 1990.
Robert then subsequently entered graduate school, focusing on changes in neuronal phenotype after peripheral axonal injury and received his PhD in Neurosciences from Case Western Reserve University.
Robert's training continued when he joined the NIH as a Pharmacology Research Associate Fellow, before joining a small molecule screening and drug discovery company, where he led several key oncology and inflammation programs. In 2006, he was introduced to Metabolon and the burgeoning field of metabolomics, where he took on roles of increasing complexity, eventually being promoted to Vice President to lead the Discovery and Translational Sciences team.
Robert joined Owlstone Medical in November 2019 where he oversees the Clinical and Translational Science team.